格隆汇2月4日丨易明医药(002826.SZ)在投资者互动平台表示，公司无原研药产品。 ...

格隆汇2月4日丨易明医药(002826.SZ)在投资者互动平台表示，公司无原研药产品。 ...

证券日报网讯2月3日，易明医药（002826）在互动平台回答投资者提问时表示，截至2026年1月30日， 易明医药股东数为17675户。 ...

证券之星消息，2月3日化学制药板块较上一交易日上涨1.41%，易明医药领涨。当日上证指数报收于 4067.74，上涨1.29%。深证成指报收于14127.1，上涨2.19%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002826 | 易明医药 | 20.98 | 9.27% | 26.92万 | | 5.59亿 | | 688513 | 苑东生物 | 68.90 | 8.85% | 6.46万 | | 4.32 Z | | 688690 | 纳微科技 | 29.00 | 7.01% | 9.39万 | | 2.65亿 | | 600513 | 联环药业 | 20.15 | 5.94% | 16.22万 | | 3.23亿 | | 300436 | 广生堂 | 107.92 | 5.78% | 13.57万 | | 14.36 Z | | 300401 | 化园生物 | 18.08 | 5.36% | 23.70万 | | 4.22亿 | | 6 ...

Policy Developments - The National Healthcare Security Administration and the National Administration of Traditional Chinese Medicine announced the inclusion of Beijing and other regions in a pilot program for disease-based payment for traditional Chinese medicine [2] Drug and Device Approvals - Heng Rui Medicine received acceptance for a new indication application for its innovative drug, injection of Carrelizumab combined with Apatinib, for the treatment of unresectable hepatocellular carcinoma [4] - Lifesun Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs, which is expected to enhance market competitiveness [5] - Eli Lilly's Metabolically Associated Fatty Liver Disease indication for Tirzepatide has been included in the list of breakthrough therapies by the National Medical Products Administration [6] Financial Reports - Yiming Pharmaceutical projected a net profit increase of 61.12% to 122.08% for 2025, driven by the growth of its core product, Miglitol tablets [8] - Innovation Medical forecasted a net loss of 26 million to 33 million yuan for 2025, primarily due to tax expenses and adjustments in healthcare policies [9] Capital Markets - Kangchen Pharmaceutical upgraded its share repurchase plan to a total of 300 million Hong Kong dollars, extending the buyback period until the next annual general meeting [11] Industry Developments - Huawei Cloud is set to launch a smart healthcare section as part of its AI "Dream Factory" initiative, aiming to integrate top medical resources and advanced technology [14] - AstraZeneca announced plans to invest 15 billion USD in China by 2030 to expand research and production capabilities [16]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002826 证券简称：易明医药 公告编号：2026-001 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年12月31日 本次业绩预告是公司财务部门的初步测算结果，具体财务数据将在2025年度报告中详细披露。公司将严 格依照相关规定和要求，及时做好信息披露工作。敬请广大投资者注意投资风险。 特此公告。 西藏易明西雅医药科技股份有限公司 董事会 单位：万元 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所审计。但公司已就业绩预告 有关事项与年报审计会计师事务所进行了预沟通，公司与会计师事务所在本报告期的业绩预告方面不存 在重大分歧。 三、业绩变动原因说明 1、报告期内，公司紧随行业发展方向及政策导向，集中资源大力发展自产产品，不断提升自产产品价 值与市场占有率，实现了核心自有产品米格列醇片的销量增长，带动整体利润提升，为公司的长期稳定 发展奠定基础； 2、本报告期非经常性损益主要来源于政 ...

专题：交易提示 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 【停牌】 002231 *ST奥维（维权） 300666 江丰电子 300344 *ST立方（维权） 【复牌】 *ST奥维：收到终止上市事先告知书股票于1月30日起停牌 无 【品大事】 美年健康：拟参与棒杰股份预重整 美年健康（002044）公告，公司拟报名参与浙江棒杰控股集团股份有限公司（简称"棒杰股份"）重整投 资人的公开招募，并指定下属全资子公司美年大健康为重整受让主体取得棒杰股份的控制权，成为棒杰 股份重整完成后的控股股东。是否具有参与资格以及最终能否成为重整投资人尚存在不确定性。 白银有色（维权）：公司黄金、白银产品的收入占总营业收入比重较低 白银有色（601212）发布股票交易异常波动及严重异常波动公告称，公司黄金、白银产品的收入占总营 业收入的比重较低。2025年上半年，公司营业收入445.59亿元，销售黄金产品收入83.18亿元，占公司营 业收入的比重18.67%，销售白银产品收入20.23亿元，占公司营业收入的比重4.54%。 天顺风能：决定对六家全资子公司实施长期停产安排 天顺风能（002531）公告 ...

格隆汇1月29日丨易明医药(002826.SZ)公布，预计2025年归属于上市公司股东的净利润7,400万元～ 10,200万元，比上年同期增长61.12%～122.08%，扣除非经常性损益后的净利润3,900万元～5,400万元， 比上年同期增长111.42%～192.74%。 报告期内，公司紧随行业发展方向及政策导向，集中资源大力发展自产产品，不断提升自产产品价值与 市场占有率，实现了核心自有产品米格列醇片的销量增长，带动整体利润提升，为公司的长期稳定发展 奠定基础。 ...

证券日报网讯1月29日，易明医药（002826）发布公告称，公司预计2025年度归属于上市公司股东的净 利润为7，400万元至10，200万元，比上年同期增长61.12%至122.08%。 ...

Group 1 - Meinian Health plans to participate in the restructuring of Zhejiang Bangjie Holdings, aiming to become the controlling shareholder after the completion of the restructuring [3] - Baiyin Nonferrous Metals reported that the revenue from gold and silver products accounted for a low proportion of total operating income, with gold sales contributing 18.67% and silver sales 4.54% in the first half of 2025 [4] - Tiens Wind Power decided to implement a long-term production suspension for six wholly-owned subsidiaries to optimize resource allocation and focus on core businesses [5] Group 2 - Tongling Nonferrous Metals indicated significant uncertainty in the price fluctuations of its main products, with a low self-sufficiency rate for copper concentrate posing supply stability risks [6] - *ST Aowei received a notice of termination of listing due to its market capitalization falling below 500 million yuan for twenty consecutive trading days [7] - Foton Motor expects a net profit increase of approximately 1551% year-on-year for 2025, driven by sales growth in new energy vehicles and overseas markets [9] Group 3 - Beimo High-tech anticipates a net profit increase of 1076.16% to 1261.87% for 2025, supported by cost control and reduced credit impairment losses [10] - Zhongke Sanhuan forecasts a net profit growth of 566.23% to 899.35% for 2025, attributed to technological innovation and improved operational efficiency [12] - Wancheng Group expects a net profit increase of 222.38% to 266.94% for 2025, driven by growth in its retail business and improved sales margins [13] Group 4 - Huayi Technology anticipates a net profit increase of 191.52% to 330.34% for 2025, benefiting from product optimization and cost reduction measures [14] - Nanmo Biology expects a net profit growth of 269.49% to 423.44% for 2025, supported by increased revenue in the biopharmaceutical sector and improved cost control [15] - Baiao Saitu forecasts a net profit increase of 384.26% to 443.88% for 2025, driven by expansion in overseas markets and recovery in the domestic biopharmaceutical industry [16] Group 5 - Hailanxin expects a net profit increase of 387.47% to 631.2% for 2025, supported by advancements in technology and increased market share in marine observation [17] - Panjiang Co. anticipates a net profit growth of 205.3% to 264.83% for 2025, driven by increased coal production and reduced costs [18] - Huaguang New Materials expects a net profit increase of 104.67% to 141.88% for 2025, with significant growth in the electronic sector [20] Group 6 - Guo Sheng Securities forecasts a net profit increase of 25.44% to 67.25% for 2025, supported by active capital market participation and growth in various business segments [25] - Shengyi Technology expects a net profit growth of 87% to 98% for 2025, driven by increased sales of copper-clad laminates [26] - Sifutian anticipates a net loss of 30 million to 45 million yuan for 2025, although this represents a significant reduction in losses compared to the previous year [27] Group 7 - Maanshan Steel expects a net loss of 1.9 billion to 2.5 billion yuan for 2025, with a substantial reduction in losses compared to the previous year [28] - Shennong Seed Industry forecasts a net profit of 90 million to 120 million yuan for 2025, marking a turnaround from previous losses [30] - Jifeng Co. anticipates a net profit of 410 million to 495 million yuan for 2025, achieving a turnaround from losses [31]